Combination effect of captopril and losartan on cell adhesion molecules and cytokines in the patients with coronary heart disease

Abstract

Abstract: AIM: To explore the effect of the combination of captopril and losartan on the sICAM-1, sVCAM-1, TNF-α, and TGF-β in the patients with coronary heart disease.METHODS: sICAM-1, sVCAM-1 and TGF-β were measured with ELISA, and TNF-αwas measured with RIA in the patients with or without the treatment of captopril and losartan.RESULTS: sICAM-1 and TNF-α decreased, and TGF-β increased distinctly in the patients given a combination of captopril and losartan compared with patients without the drugs.sVCAM-1 had the tendency of decrease in combined therapy, but no significant difference showed compared with the control patients. .CONCLUSION: The combination of captopril and losartan has the effects on the cell adhesion molecules and cytokins in patients with coronary heart disease.

Key words: captopril, losartan, cell adhesion molecules, cytokins, coronary heart disease

CLC Number:

R969.4
R452

LIANG Xu-Guo, PAN Qi-Xing. Combination effect of captopril and losartan on cell adhesion molecules and cytokines in the patients with coronary heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(2): 159-161.

References

1 Blaufarb IS, Sonnenblick.The rein-angiotensin system in left ventricular remodeling[J].Am J Cardiol, 1996, 77:8c-16c
2 Liu YH, Yang XP, Sharov VG, et al.Effect of angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure.Role of kinins and angiotensin II type 2 receptors[J].J Clin Invest, 1997, 99:1926-35
3 Yang BC, Phillips MI, Ambuehl PEJ, et al.Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts[J].Circulation, 1997, 96: 922-6
4 Ambrose J, Pribnow DG, Girand GD, et al.Angiotensin II type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle[J].J Am Soc Nephrol, 1999, 10:129-36
5 Crea F, Biassucci LM, Buffon A, et al.Role of inflammation in the pathogenesis of unstable coronary artery disease[J].Am J Cardiol, 1997, 80(5A):10E-6E
6 Van der Wal AC, Becker AE, van der Loos CM, et al.The site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology[J].Circulation, 1994, 89:36-44
7 Jovinge S, Hultardh-Nilson A, Regnstrom J, et al.TNF-αactivates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta[J].Arterioscler Thromb Vasc Biol, 1997, 17:490-7
8 Bray P, Agrotis A, Bobik A.Transforming growth factor-beta and receptor tyrosine-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats[J].Hypertension, 1998, 31:986-94
9 Andrew D, Brann G, Jean A, et al.Circulation endothelial cell/ leukocyte adhesion molecules in ischemic disease[J].Br J Haematology, 1996, 95:263-5

[1]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Evinacumab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
[2]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Inclisiran [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
[3]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
[4]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[5]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[6]	YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili. Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
[7]	LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian. Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
[8]	CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia. Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
[9]	PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.
[10]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[11]	WANG Shiqi, HU Huawen, CHEN Xiaomin, WANG Jian, YE Honghua. Effects of different intensities of warfarin on patients with coronary atherosclerotic heart disease complicated with atrial fibrillation: a comparative study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1410-1414.
[12]	HUANG Xu-hui, SUN Hong, CAI Jia-qin, JU Ming-yu. URAT1 allele 6092(T/C) polymorphism influence uricosuric action of losartan in hyperuricemia patients with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 435-440.
[13]	WU Ji-chu, LUO Can-xiang, OU YANG Ze-wei. Amiodarone and losartan on recurrence and atrial structure for chronic atrial fibrillation after RFCA [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 318-322.
[14]	CHEN Lu-lu, TAN Zhi-rong, YANG Guo-ping, CHEN Xiao-ping, WANG Yi-cheng, CHEN Yao, TIAN Ying-ying, ZHOU Lu-ping, WANG Wen-ping, HE Jia-qi, ZHOU Hong-hao, OUYANG Dong-sheng. Bioequivalence of losartan potassium tablets and the influence of CYP2C9^*3 polymorphism on the metabolism of losartan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 175-181.
[15]	CHEN Jiang-ying, YAN Zhen-wen, ZHANG Su-ping, YIN Yi-chen. Protection of losartan on cultured rats hippocampal neurons odels of hypoglycemia anoxia injury in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 984-987.